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Multiple sclerosis (MS) is a chronic autoimmune disease that targets myelinated axons in the central nervous system.
Headache has been reported as a subtle symptom of the onset of MS, with a variable frequency of 1.6–28.5%;
however, it remains unclear whether headache is a true symptom of MS onset. Here, we report the case of a female
patient who had a history of migraine without aura and experienced worsening of migraine-headache symptoms as
the initial manifestation of MS. Three similar cases were reported previously; however, unlike this case, those cases had
no history of migraine without aura. In our case, we excluded factors that could trigger migraine attacks, such as
changes in weather, drugs, alcohol, caffeine withdrawal, stress, fatigue, lack of sleep, hormonal therapy, diet, and
hunger. The patient had one episode of MS attack with the simultaneous presence of asymptomatic gadolinium-
enhancing and non-enhancing lesions, including hyperintense lesions in the bilateral periventricular white matter,
body of the corpus callosum, and periaqueductal grey matter, as observed on the T2-weighted images obtained at the
first brain magnetic resonance imaging. In addition, after the injection of gadolinium contrast, ring enhancement over
these lesions was noted in T1-weighted images, which was suggestive of active demyelination. MS was diagnosed
according to the McDonald criteria (2010 revision). We conclude that MS with periaqueductal grey matter involvement
may present with worsening migraine. It is important to be cautious if any secondary causes exist, especially when the
patient has a history of migraine without aura. MS should be one of the differential diagnoses in young women
showing a change in headache pattern or poor clinical drug response to migraine treatment accompanied by
episodes of focal neurological deficit. Failure to recognize MS may lead to inappropriate treatment and worse
prognosis; early diagnosis in patients with MS is essential to improve their clinical outcomes and quality of life.
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Multiple sclerosis (MS) is a chronic autoimmune disease
that affects the myelinated axons in the central nervous
system (CNS) [1]. This disease affects women more fre-
quently than men. The estimated female-to-male ratio of
MS incidence increased from 1.4 in 1955 to 2.3 in 2000,
according to a systematic review of 28 epidemiologic
studies [2]. The average age of onset of MS is 30 years,
and the disease starts approximately five years earlier in
women than it does in men [3]. MS symptoms at pres-
entation vary individually and are unpredictable [4].
Headache is not generally regarded as a symptom of MS,
although it occurs in more than half of the cases of MS* Correspondence: fuji-yang@yahoo.com.tw
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in any medium, provided the original work is p[5]. Whether headache is a symptom of MS onset remains
an open question [5]. Recently, we encountered a woman
with MS, as diagnosed according to the 2010 revisions of
the McDonald criteria, whose initial presentation was
worsening migraine [6]. After steroid therapy, the patient
returned to the remission stage without obvious neuro-
logical sequel, and the headache improved significantly.Case presentation
A 33-year-old woman experienced severe right- or left-
sided parietal–temporal throbbing headache accompanied
by blurred vision, photophobia, vomiting, and anorexia at
a frequency of 1–2 days per month since she was an ado-
lescent. She was diagnosed with migraine without aura
and received no prophylactic treatment. One month ago,
she exhibited more severe, right-sided, parietal–temporal
throbbing headaches characterized by a prolongedpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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per month. She showed a poor medical response to suma-
triptan and naproxen therapy. A few days after sumatrip-
tan and naproxen therapy, she experienced the first MS
episode of blurred vision over both the eyes and right fa-
cial numbness, which subsided quickly and spontaneously
after 24 hours. Because the symptoms subsided quickly
after 24 hours, the patient did not come to our outpatient
department (OPD) at that time. No objective evidence of
alteration of vision or facial sensation was observed.
According to our detailed recordings of the patient’s his-
tory, she had never experienced these symptoms before.
Because of these new symptoms, the patient underwent
brain magnetic resonance imaging (MRI), and some
hyperintense lesions in the bilateral periventricular white
matter, body of corpus callosum, and periaqueductal grey
matter (PAG) were noted on the T2-weighted images.
After gadolinium contrast injection, ring enhancement
over these lesions was noted on T1-weighted images. In
the sagittal view, MS plaques with a typical perpendicular
orientation at the callososeptal interface were notedFigure 1 Hyperintense lesions in the bilateral periventricular white matt
grey matter (arrowhead) are noted on the T2-weighted image. After gad
on the T1-weighted image (curved arrows), which is suggestive of active dem
perpendicular orientation at the callososeptal interface are noted (Dawson’s fin(Dawson’s fingers) (Figure 1). The patient was diagnosed
with definite MS according to the McDonald criteria
(2010 revision). The MS diagnosis was based on the re-
cording of one episode of MS attack and the evidence of
simultaneous gadolinium-enhancing and non enhancing
lesions. The patient refused to receive disease-modifying
therapy because her symptoms were relieved and the
headache subsided gradually.
Two months later, the patient was admitted to the
neurology department of our hospital because of bilat-
eral numbness of the lower legs, unsteady gait, difficulty
in defecation, and urine retention for the past week. In
addition, worsened migraine was noted again. Neuro-
logical examination showed bilateral pinprick-sensation
and vibration impairment over the L1–L2 dermatome,
positive Romberg test results, poor coordination, and
short steps with wide-based gait. The follow-up brain MRI
revealed that the above-mentioned lesions had increased
in number and size, as observed on T2-weighted images.
After gadolinium contrast injection, more prominent ring
and incomplete ring enhancements over these lesions,er (arrow), body of the corpus callosum (arrow), and periaqueductal
olinium contrast injection, ring enhancement over these lesions is noted
yelination. In the sagittal view, multiple sclerosis plaques with a typical
gers) (black arrow).
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images. In the sagittal view, MS plaques with an increased
number of Dawson’s fingers were noted (Figure 2). These
signs were suggestive of disease progression with active
demyelination. On the basis of our physical observation,
we performed a low thoracic and lumbar spine MRI,
which showed a hyperintense lesion in the spinal cord (T9
level) on T2-weighted images and enhancement after
gadolinium injection (Figure 3).
MS with spinal cord involvement was considered. The
cerebrospinal fluid (CSF) analysis performed after admis-
sion to exclude other possible infectious causes showed
no white cells and normal glucose (70 mg/dL) and pro-
tein (26 mg/dL) levels. CSF tests were negative for virus
isolation and for Gram stain and culture. No oligoclonal
bands were found. Serum analyses for presence of
rheumatoid factor (RF), antibodies against nuclear anti-
gen, and anticardiolipin immunoglobulins G and M
yielded negative results; in addition, the levels of the C3
(90.7 mg/dL) and C4 (18.5 mg/dL) complement were
normal. Furthermore, the anti-HIV and rapid plasmaFigure 2 Two months later, the hyperintense lesions located in the bila
callosum (arrow), and right periaqueductal grey matter (arrowhead) we
images. After gadolinium contrast injection, more prominent ring and incom
image (curved arrows). In the sagittal view, multiple sclerosis plaques with anreagin (RPR) tests were negative. The erythrocyte sedi-
mentation rate (ESR) and C-reactive protein (CRP) levels
were <0.10 mg/dL. Assessment of visual evoked poten-
tials (VEPs) revealed that the P100 wave latencies were
134 ms and 137 ms in the right and left eye, respectively;
the amplitude was lower in the right eye. Compared to
the normal values, the amplitudes were prolonged by
over 20% in both the eyes, which indicated definite in-
volvement of the optic nerves. After five days of methyl-
prednisolone therapy, the clinical condition returned to
the remission stage, without evident neurological deficit,
and the patient’s headache improved significantly. After
the second episode, we discussed the patient’s condition
with her family and shifted the patient to immunomodu-
latory treatment with subcutaneous injection of 44 μg of
interferon beta-1a thrice a week, with regular outpatient
department follow-up.
Discussion
Here, we report the case of a patient who showed wors-
ening migraine as the initial presenting symptom of MS.teral periventricular white matter (arrow), body of the corpus
re increased in number and size, as observed on T2-weighted
plete ring enhancement over these lesions is noted on the T1-weighted
increased number of Dawson’s fingers are noted (black arrow).
Figure 3 Low thoracic and lumbar spine MRI showing a hyperintense lesion in the spinal cord (T9 level), which is observable on the
T2-weighted image (arrow). The lesion exhibits contrast enhancement after gadolinium injection (curved arrow).
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(2010 revision). This patient had one episode of MS attack
and exhibited the simultaneous presence of asymptomatic
gadolinium-enhancing and non-enhancing lesions on the
first brain MRI scan. The McDonald criteria for category
III were established.
Patients with MS have a high prevalence of headache;
headache occurs more commonly in patients with MS
(27%) than in matched controls (12%) [7]. D’Amico and
colleagues reported a 57.7% lifetime prevalence of head-
ache in 137 patients with clinically definite MS [8].
However, it is unclear whether headache is a symptom
of the onset of MS. Kurtzke et al. [9] considered head-
ache as a subtle symptom of MS onset, with a variable
frequency of 1.6–28.5%. This variation in frequency
might be explained by differences in study design and
patient inclusion criteria. Ophthalmoplegic migraine-like
headache [10], complicated migraine [11], short-lasting
unilateral neuralgiform headache attacks with conjunc-
tival injection and tearing (SUNCT) [12], and cluster tic
syndrome [13] have also been reported in single MS
cases. Fragoso and Brooks [14] described a single case
and Yetimalar et al. [15] reported the cases of two youngwomen with migraine onset as the only symptom of the
first episode of MS. These cases were different from our
patient because they had no history of migraine without
aura.
To our knowledge, there is no description in the litera-
ture of patients presenting with worsening migraine
symptoms without neurological signs as the first episode
of MS. When the initial symptoms of MS are worsening
migraines and changes in headache patterns, they may
be discounted as a recurrent event and ignored. Our
study suggest that it is important to consider the possi-
bility of MS in patients with worsening migraine symp-
toms accompanied by episodes of focal deficit and to
follow-up these patients regularly.
Tortorella et al. found that patients with migraine had
supratentorial lesions chiefly located in the frontal lobes
and periventricular white matter and noted no difference
in the number of supratentorial lesions between patients
with migraine with or without aura [16]. In our case, the
first brain MRI scan showed signs that were unlike the
migraine lesions at the locations mentioned above, and
there was damage to the periventricular and infratentorial
PAG regions.
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changes in weather, drugs, alcohol, caffeine withdrawal,
stress, fatigue, lack of sleep, hormonal therapy, diet, and
hunger [17]. In our case, none of the above-mentioned
factors was found. We hypothesize that stress causes in-
flammation in general, and particularly in MS, because
stress-related neuropeptides activate the excretion of in-
flammatory molecules by microglia and mast cells [18].
Although no obvious stress was observed in our case, a
hidden stress may have caused the acute MS attacks. As
observed in our case, MS may be considered as one of the
differential diagnoses of acute-migraine-like episodes.
The PAG modulates pain via the descending system
and exerts an antinociceptive effect to the peripheral af-
ferent system. Gee et al. showed that patients having MS
with a plaque located within the PAG region displayed a
four-fold increase in migraine-like headaches [19]. In
our experience, common migraine attacks generally re-
quire no further imaging examinations. However, in our
case, worsening migraine followed by an episode of focal
neurological deficit indicated that we should look for
any secondary causes of the symptoms. The involvement
of the PAG region may explain why this case presented
initially with worsening migraine headache without clin-
ical response. The patient initially refused treatment
when MS was diagnosed because of symptom relief;
however, unfortunately, the symptoms recurred two
months later. Although there is no cure for MS, the
diagnosis of the disease and early initiation of an appro-
priate treatment are the best strategies to prevent severe
neurological deficits.
Moreover, the more frequent administration of the
IFNb preparation, as performed here, seems better than
the administration of IFNb-1a just once a week [20,21].
In fact, in a previous study worsening of pre-existing
headaches or de novo headaches were found only in pa-
tients with MS who received interferon therapy, and not
in those who received other disease-modifying therapies
[22]. Compared to natalizumab (NTZ), IFNb might
cause a continued increase in the frequency and severity
of migraine in cases of MS [23]. However, NTZ was ap-
proved by the US Food and Drug Administration as a
second-line monotherapy for patients with MS who ex-
hibit no response to other immunomodulating drugs
[24]. In addition, glatiramer acetate is not available cur-
rently in our hospital. In our case, the patient receives a
subcutaneous injection of interferon beta-1a thrice a
week after well discussion with the patient.
Conclusions
We demonstrated the importance of PAG involvement
in a patient presenting with acute worsening migraine
headache as an initial manifestation of MS. The presence
of worsening migraine as a symptom of MS could leadto diagnostic difficulties. Moreover, this symptom may
be easily ignored in patients with a migraine history. MS
should be one of the differential diagnoses in young
women showing a change in headache pattern or poor
clinical drug response to headache treatment accompan-
ied by episodes of focal neurological deficit. Failure to
recognize MS may lead to inappropriate treatment and
worse prognosis; therefore, early diagnosis in patients
with MS is essential to improve their clinical outcomes
and quality of life.Consent
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